糖尿病合并慢性肾脏病患者的管理:KDIGO争议会议结论
糖尿病是多数发达国家终末期肾病的首要病因,肾病患者心血管病和死亡风险显著升高。本次KDIGO争议会议评估了最佳血糖控制、现有降糖药安全性及改善肾脏与心血管结局的新疗法。
要点
- 糖尿病是全球慢性肾脏病和终末期肾病的主要病因,患者心血管风险显著升高。
- 会议评估了最佳血糖控制、现有降糖药安全性及在研新疗法的证据。
- 针对糖尿病合并慢性肾脏病患者的新疗法正在开发中。
核心结论
- 本次KDIGO争议会议评估了糖尿病合并慢性肾脏病患者的最佳血糖控制、现有降糖药安全性及改善肾脏与心血管结局的新疗法。
研究设计与样本
- 本次为KDIGO争议会议,旨在评估糖尿病合并慢性肾脏病患者的当前知识状态。
主要发现
- 糖尿病是多数发达国家终末期肾病的首要病因,全球终末期肾病患者数量增长与糖尿病增加平行。
- 糖尿病患者合并肾脏病与心血管疾病和死亡风险显著升高相关。
- 多种新疗法和针对糖尿病合并慢性肾脏病患者的在研药物正在开发中。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.
引用
- Perkovic V, Agarwal R, Fioretto P, et al. Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2016. PMID: 27884312. doi:10.1016/j.kint.2016.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。